Alopecia Treatment in Cuba: Placental Histotherapy & Advanced Dermatology

Alopecia refers to hair loss from the scalp or body. It affects millions of people worldwide and can have significant psychological and social impact, particularly in cultures where hair carries strong identity and social significance. The most common forms include androgenetic alopecia (male and female pattern baldness), alopecia areata (autoimmune hair loss), telogen effluvium (stress-related shedding), and cicatricial alopecia (scarring hair loss).

Cuba's dermatology centers offer unique treatment approaches for alopecia, including placental histotherapy products developed at the Placental Histotherapy Center in Havana — the world's only institution dedicated to the research, development, and clinical application of placental-derived therapies for dermatological conditions. These biotechnological treatments aim to stimulate hair follicle activity and promote hair regrowth using bioactive compounds derived from human placenta.

The Cuban approach combines topical biotech therapies with comprehensive dermatological care, offering international patients access to treatments not widely available in other countries. The Placental Histotherapy Center has treated patients from over 60 countries and its products — including Melagenin Plus® for vitiligo and related placental extracts for alopecia — are registered in multiple nations.

Cuba's dermatology infrastructure includes specialized centers in Havana with experienced dermatologists, trichologists, and dermatopathologists who collaborate to diagnose the underlying cause of hair loss and design personalized treatment protocols. This multidisciplinary approach distinguishes the Cuban model and ensures that each patient receives care tailored to their specific type and stage of alopecia.

Androgenetic alopecia presents as gradual thinning of hair on the scalp, typically following a recognizable pattern — receding hairline and crown thinning in men (Hamilton-Norwood pattern), and diffuse thinning with widening of the central part in women (Ludwig pattern). It is the most common form of hair loss, affecting approximately 50% of men by age 50 and a significant proportion of postmenopausal women.

Alopecia areata is an autoimmune condition that causes sudden, patchy hair loss — round or oval bald patches that can appear within days or weeks. In severe cases, it can progress to total scalp hair loss (alopecia totalis) or total body hair loss (alopecia universalis). Alopecia areata affects approximately 2% of the global population and can occur at any age, though it most commonly begins before age 40.

Telogen effluvium causes diffuse hair shedding across the scalp, often triggered by severe stress, illness, surgery, childbirth, hormonal changes, nutritional deficiencies (particularly iron, vitamin D, and zinc), or certain medications. The shedding typically begins 2–3 months after the triggering event and is usually reversible once the underlying cause is addressed.

Cicatricial (scarring) alopecia involves inflammation that destroys hair follicles and replaces them with scar tissue, causing permanent hair loss. Early diagnosis and treatment are critical to halt follicular destruction and preserve remaining hair. The type, pattern, and duration of hair loss guide treatment decisions, and a dermatological assessment is essential to determine the underlying cause.

Diagnosis involves a thorough dermatological examination, assessment of hair loss pattern and distribution, pull test (gentle traction on hairs to assess shedding activity), trichoscopy (scalp examination with a dermatoscope for magnified visualization of hair shafts and follicles), and sometimes scalp biopsy for histopathological analysis. The dermatoscopic examination can reveal characteristic patterns that help differentiate between types of alopecia.

Blood tests may be ordered to check for underlying conditions that contribute to hair loss, including thyroid dysfunction (TSH, free T4), iron deficiency (ferritin, serum iron), vitamin D levels, hormonal imbalances (testosterone, DHEA-S, prolactin in women), autoimmune markers (ANA, anti-TPO for autoimmune thyroiditis), and nutritional deficiencies (zinc, B12, folate). These investigations help identify treatable underlying causes.

Cuban dermatology specialists perform a comprehensive assessment to determine the type and cause of alopecia, including evaluation of contributing factors such as stress, nutrition, medications, family history of hair loss, and recent illness or surgery. The diagnostic process may also include trichogram (microscopic examination of plucked hairs to assess the anagen-to-telogen ratio) and, in selected cases, scalp biopsy with immunofluorescence.

Accurate diagnosis is the foundation of effective treatment. The type of alopecia determines the treatment approach — androgenetic alopecia requires different interventions than alopecia areata or cicatricial alopecia. Cuba's dermatology team ensures that each patient receives the correct diagnosis before treatment begins, maximizing the chances of successful outcomes.

The severity of alopecia varies widely and significantly impacts treatment outcomes. For androgenetic alopecia, the Hamilton-Norwood (men) and Ludwig (women) classification systems describe the extent of hair loss, ranging from minor temporal recession to extensive baldness. Early-stage androgenetic alopecia responds best to treatment, as hair follicles are still active and capable of producing hair.

Alopecia areata is classified by extent: patchy (most common, affecting less than 50% of scalp), extensive (more than 50% of scalp), alopecia totalis (complete scalp hair loss), and alopecia universalis (complete body hair loss). The Severity of Alopecia Tool (SALT) score quantifies scalp hair loss and helps track treatment response. Earlier-stage, patchy alopecia areata has the highest regrowth potential.

For cicatricial alopecia, the activity stage (active inflammation vs. burned-out scarring) is critical. Active inflammatory cicatricial alopecia requires aggressive anti-inflammatory treatment to halt follicular destruction. Once follicles are destroyed and replaced by scar tissue, regrowth is not possible, and treatment focuses on preventing further loss and managing cosmetic concerns.

Cuba's dermatology team assesses each patient's alopecia stage and follicle status to determine treatment feasibility and set realistic expectations. Patients with active follicles and earlier-stage disease have the best prospects for regrowth, while those with long-standing, extensively damaged follicles may benefit from supportive and cosmetic approaches.

Cuba's Placental Histotherapy Center has developed topical treatments derived from human placenta that may be beneficial for certain types of alopecia. These products contain growth factors, lipoproteins, and bioactive compounds that aim to stimulate hair follicle activity, improve scalp microcirculation, reduce inflammation, and promote hair regrowth. The placental extract is processed under stringent pharmaceutical standards to ensure safety and consistency.

The mechanism of action involves multiple pathways: growth factors in the placental extract stimulate cellular proliferation in the hair follicle bulb, lipoprotein fractions improve nutrient delivery to the follicle, and anti-inflammatory components help modulate the autoimmune processes underlying alopecia areata. This multimodal approach distinguishes placental histotherapy from single-molecule treatments.

Treatment protocols are personalized based on the type of alopecia, extent of hair loss, scalp condition, and individual factors such as age, hormonal status, and nutritional status. The treatment is applied topically and may be combined with other dermatological approaches such as phototherapy (narrowband UVB), topical corticosteroids, minoxidil, intralesional corticosteroid injections for alopecia areata, and nutritional supplementation.

Best results are typically seen in patients with early-stage alopecia areata and androgenetic alopecia, where hair follicles are still active and capable of producing hair. Treatment is delivered by experienced dermatology specialists in Havana's specialized dermatology centers, with regular monitoring of progress through clinical photography, trichoscopy, and SALT scoring for alopecia areata patients. Treatment cycles typically last several weeks and may be repeated based on response.

Cuba's alopecia treatments are suitable for patients with various types of hair loss, particularly early-stage alopecia areata (patchy type, less than 50% scalp involvement) and androgenetic alopecia (both male and female pattern). Patients with active, inflamed follicles have the highest regrowth potential, and early intervention improves outcomes.

Patients with long-standing cicatricial alopecia (where follicles are permanently destroyed and replaced by scar tissue) may have limited regrowth potential. In these cases, treatment may focus on halting further follicular destruction and managing cosmetic concerns. A dermatological assessment is required to determine follicle status and the most appropriate treatment approach.

General eligibility criteria include: confirmed dermatological diagnosis of alopecia, absence of active scalp infection or malignancy, adequate overall health for travel, and realistic expectations regarding treatment outcomes. Patients with autoimmune conditions associated with alopecia (thyroid disease, vitiligo, type 1 diabetes) should have these conditions stabilized before beginning treatment.

To begin the eligibility review, submit photographs of affected areas (close-up and wide shots of the scalp), dermatologist's report with diagnosis, duration and pattern of hair loss, any trichoscopy or biopsy results, associated medical conditions, current medications, and recent blood test results (thyroid, iron, vitamin D) through our consultation form. Our dermatology team reviews these to determine eligibility and build a personalized treatment plan.

Alopecia treatment typically requires 2–4 weeks in Cuba for the initial treatment cycle, though some patients may benefit from extended or multiple cycles depending on the type and severity of alopecia. International patients receive comprehensive logistical support including medical visa assistance, airport reception, accommodation near the dermatology center, translation services, and ground transportation.

A detailed cost estimate is provided after dermatology review. The program includes dermatology consultations, placental histotherapy medications, phototherapy sessions if needed, trichoscopy monitoring, and all logistics including accommodation and meals. Costs vary based on the extent of affected areas, treatment duration, and whether combination therapies are required.

Our international patient services team coordinates all arrangements for patients and accompanying family members, ensuring a comfortable and well-supported treatment experience. Multilingual coordinators speaking Arabic, Turkish, French, English, Spanish, Russian, and Portuguese are available to assist patients from the Middle East, Africa, Europe, and Latin America.

For patients traveling from regions with limited access to placental histotherapy — including the Gulf states, North Africa, sub-Saharan Africa, and parts of Asia — Cuba offers a unique opportunity to access these therapies. Our team has experience coordinating care for international patients and can facilitate connections with previous patients from your region who have undergone treatment in Cuba.